FPRX earnings call for the period ending March 31, 2019.
News & Analysis: Five Prime Therapeutics
FPRX earnings call for the period ending December 31, 2018.
Five Prime Therapeutics and Bristol-Myers Squibb may have a viable pancreatic cancer drug after all.
A key development deal with a leader in immuno-oncology sent shares higher last month.
No biotech experience required.
A new license and collaboration agreement with Bristol-Myers Squibb sends Five Prime Therapeutics' shares soaring today.
Aratana Therapeutics, Celldex Therapeutics, and Five Prime Therapeutics have been feeling the wrath of this moody market of late. Here's why one Fool believes the steep sell-offs in these names represent a compelling buying opportunity now.
Three Motley Fool analysts tell us which emerging biotechnology stocks they're watching in 2015.
Wall Street has been snapping up shares of Prothena and Five Prime Therapeutics. Here's why.
Organic pipeline innovation and acquisitions aside, this has been the biggest driver of Big Pharma's success in recent years.